Pralsetinib is a selective and next-generation RET inhibitor (IC50: 0.3-0.4 nM for WT RET, RET mutants V804L, V804M, M918T, and CCDC6-RET fusion). BLU-667 is an effective and selective inhibitor of RET mutations, fusions, and predicted resistant mutants.

TQ0277L

C27H33ClFN9O2

570.07

BLU 667;Pralsetinib hydrochloride;BLU-667;BLU667;Pralsetinib HCl;Pralsetinib HCl (2097132-94-8 free base)

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years